Posted in | Nanobusiness

NanoLogix Reports Increased Sales of BNP and BioNanoFilter Bacteria Detection Kits in Third Quarter

Published on November 14, 2012 at 7:31 AM

NanoLogix (OTC Markets: NNLX) is the subject of a featured news article released last week by the US Environmental Protection Agency. The article covers the progress of an ongoing Cooperative Research and Development Agreement (CRADA) in place between the EPA and NanoLogix. The objective of the CRADA is to develop a comprehensive water quality test kit for use in testing drinking and source waters in the EPA’s ten regions.

The article can be accessed on the EPA’s site at the following link: http://www.epa.gov/nerl/features/nanologix.html

NanoLogix is pleased to announce sales experienced a significant increase in Q3. Essentially all of Q3 and current sales have been, and are, directly to the US Federal government or to Corporations for use on classified US Government projects. These sales are comprised of BNP kits and filled Petri plates. Major marketing for BNP and BioNanoFilter (BNF) bacteria detection kits is pending publication of two recently completed third-party studies in peer-reviewed science journals.

The company has had increasing interest in both its BioNanoPore (BNP) Petri-based sandwiched-membrane bacteria detection kits and also in standard filled Petri plates, both packed in NanoLogix’s proprietary extended-life packaging. The internally developed patent pending packaging enables storage of both BNP and Petri for over one year in cold storage, and for at least three months at room temperature.

NanoLogix is honored to welcome Giles Manley, MD to the NanoLogix Science Advisory Board (SAB). Dr. Manley brings a wealth of medical, legal and business knowledge to the SAB.

Dr. Manley’s acceptance statement: “I am grateful for the invitation, and very excited about being part of NanoLogix by serving on their Science Advisory Board. What NanoLogix has accomplished over the last several years is truly amazing. There is no comparable system in the world that can deliver bacterial identification as cost effectively, quickly and accurately as their BNF and BNP product line… Through my career I have formed acquaintances with the Chiefs of Obstetrics at some of the top medical institutions in our country. I will make a concerted effort to get the necessary trials started and finished at places such as Harvard, Johns Hopkins and other institutions. I am hopeful that by the end of 2013 the standard for GBS screening will include our near-15 minute test at time of labor.”

Source: http://nanologix.com/

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit